Tigecycline Evaluation Surveillance Trial (TEST) United States in vitro antibacterial activity against selected species of glucose non-fermenting organisms
Abstract number: 1134_02_14
Bouchillon S., Stevens T., Johnson B., Johnson J., Hoban D., Hackel M., Person M., Dowzicky M.
Glucose non-fermenting Gram negative rods are known to be highly resistant in hospital settings and have always been a challenge for clinicians and hospital infection control. The degree or type of resistance may be due to several sophisticated mechanisms such as production of broad spectrum beta-lactamases, efflux pumps and altered membrane permeability, inactivating most classes of antimicrobials that are available for treatment (cephalosporins, carbapenems, aminoglycosides, fluoruquinolones). Tigecycline, a member of a new class of antimicrobials (glycylcyclines), has been shown to have potent expanded broad spectrum activity against most species of Enterobacteriaceae and selected species of non-fermenters, as well as Gram positives, atypicals and anaerobes. The TEST program determined the in vitro activity of tigecycline compared to amikacin, ampicillin, imipenem, cefepime, ceftazidime, ceftriaxone, levofloxacin, minocycline and piperacillin/tazobactam against members of Acinetobacter spp. and Pseudomonas aeruginosa collected from hospitals in the United States.
A total of 1687 clinical isolates were identified to the species level at each participating site and confirmed by the central laboratory. Isolates were collected throughout 2004. Minimum Inhibitory Concentration (MICs) were determined by the local laboratory using broth microdilution panels and interpreted according to NCCLS guidelines.
Tigecycline's activity against P. aeruginosa showed a MIC90 of (16 mcg/ml. Towards A. baumannii (n = 849), which cephalosporins were ineffective, Tigecycline showed the lowest MIC50/MIC90 of 0.5/2 mcg/ml outperforming amikacin MIC50/MIC90 4/32, imipenem MIC50/MIC90 0.5/16 and minocycline MIC50/MIC90 1/8. Similar findings were found in other species of Acinetobacter genus.
The presented data suggest that tigecycline may be an effective and reliable therapeutic option against strains of Acinetobacter spp., including multi-drug resistant strains regardless of degree or type of resistance.
|Session name:||XXIst ISTH Congress|
|Back to top|